Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.

Although past reports have identified a variety of prognostic factors in patients with severe chronic heart failure, previous studies have not evaluated the interaction of prognostic variables and drug treatment. We analyzed the association of 30 clinical, hemodynamic, and biochemical variables with survival in 203 consecutive patients with severe heart failure; all variables were assessed just before initiation of treatment with a variety of vasodilator drugs, and all patients were subsequently followed for 6 to 94 months. By regression analysis, pretreatment serum sodium concentration was the most powerful predictor of cardiovascular mortality, with hyponatremic patients having a substantially shorter median survival than did patients with a normal serum sodium concentration (164 vs 373 days, p = .006). The unfavorable prognosis for hyponatremic patients appeared to be related to the marked elevation of plasma renin activity that we noted in these individuals (10.0 +/- 2.0 ng/ml/hr), since hyponatremic patients fared significantly better when treated with angiotensin converting-enzyme inhibitors than when treated with vasodilator drugs that did not interfere with angiotensin II biosynthesis (median survival 232 vs 108 days, p = .003). In contrast, there was no selective benefit of converting-enzyme inhibition on the survival of patients with a normal serum sodium concentration, in whom plasma renin activity was low (1.9 +/- 0.3 ng/ml/hr). This interaction between serum sodium concentration, drug treatment, and long-term outcome suggests that the renin-angiotensin system may exert a deleterious effect on the survival of some patients with chronic heart failure, which can be antagonized by converting enzyme inhibition, and provides a clinical counterpart for the similar prognostic role that has been postulated for angiotensin II in experimental preparations of heart failure.

[1]  J. Cohn,et al.  Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.

[2]  T. Lohmeier,et al.  Control of glomerular filtration rate by renin-angiotensin system. , 1977, The American journal of physiology.

[3]  B. Greenberg,et al.  Results of Long‐term Vasodilator Therapy in Patients with Refractory Congestive Heart Failure , 1981, Circulation.

[4]  R. Gorlin,et al.  Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. , 1980, The New England journal of medicine.

[5]  P. Cannon,et al.  Participation of the prostaglandins in the control of renal blood flow during acute reduction of cardiac output in the dog. , 1981, The Journal of clinical investigation.

[6]  J. Hollifield.  Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension. , 1984, The American journal of medicine.

[7]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[8]  G. L. Neifeld.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure , 1985 .

[9]  M. Packer,et al.  Sudden unexpected death in patients with congestive heart failure: a second frontier. , 1985, Circulation.

[10]  F. Smith,et al.  The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. , 1976, The Journal of clinical investigation.

[11]  N. Fineberg,et al.  Abnormalities of sodium and H2O handling in chronic obstructive lung disease. , 1982, Archives of internal medicine.

[12]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[13]  W. Grossman,et al.  Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? , 1985, Circulation.

[14]  V. Arroyo,et al.  Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. , 1981, Annals of internal medicine.

[15]  B. Massie,et al.  Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. , 1985, The American journal of cardiology.

[16]  J. W. Aiken,et al.  Angiotensin II Stimulation of Renal Prostaglandin Synthesis Elevates Circulating Prostacyclin in the Dog , 1980, Journal of cardiovascular pharmacology.

[17]  J. Cohn,et al.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[18]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[19]  S. Massry,et al.  NEUROLOGICAL MANIFESTATIONS AND MORBIDITY OF HYPONATREMIA: CORRELATION WITH BRAIN WATER AND ELECTROLYTES , 1976, Medicine.

[20]  H. Burchell,et al.  Focal myocarditis associated with pheochromocytoma. , 1966, The New England journal of medicine.

[21]  S. Yusuf,et al.  Potential for altering the natural history of congestive heart failure: need for large clinical trials. , 1985, The American journal of cardiology.

[22]  G. Riegger,et al.  Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting-enzyme blockade. , 1984, The American journal of cardiology.

[23]  J. Brown,et al.  Renin relationships in congestive cardiac failure, treated and untreated. , 1970, American heart journal.

[24]  M. Packer,et al.  Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. , 1984, Journal of the American College of Cardiology.

[25]  C. Furberg,et al.  Effect of vasodilators on survival in chronic congestive heart failure. , 1985, The American journal of cardiology.

[26]  M. Packer.  Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution* , 1985 .

[27]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[28]  P. Martorana.  The role of cyclic AMP in isoprenaline‐induced cardiac necroses in the rat * , 1971, The Journal of pharmacy and pharmacology.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  Shebuski Rj,et al.  Angiotensin II stimulation of renal prostaglandin synthesis elevates circulating prostacyclin in the dog. , 1980 .

[31]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[32]  R. Anderson,et al.  Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion. , 1974, The Journal of clinical investigation.

[33]  J. Halperin,et al.  Determinants of clinical response and survival in patients with congestive heart failure treated with captopril. , 1982, American heart journal.

[34]  K. Swedberg,et al.  PROLONGATION OF SURVIVAL IN CONGESTIVE CARDIOMYOPATHY BY BETA-RECEPTOR BLOCKADE , 1979, The Lancet.

[35]  M. Packer,et al.  Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. , 1984, Annals of internal medicine.

[36]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[37]  M. Moeschberger,et al.  Factors influencing the one-year mortality of dilated cardiomyopathy. , 1984, The American journal of cardiology.

[38]  N. Breslow.  Covariance analysis of censored survival data. , 1974, Biometrics.

[39]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[40]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[41]  M. Brown,et al.  Hypokalemia from beta2-receptor stimulation by circulating epinephrine. , 1985, The New England journal of medicine.

[42]  G. Riegger,et al.  Antidiuretic hormone in congestive heart failure. , 1982, The American journal of medicine.

[43]  J. Cohn,et al.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. , 1985, Annals of internal medicine.

[44]  M. Packer,et al.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.

[45]  M. Packer,et al.  Efficacy of captopril in low-renin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. , 1984, The American journal of cardiology.

[46]  R. Gorlin,et al.  Determinants of Drug Response in Severe Chronic Heart Failure. 1. Activation of Vasoconstrictor Forces During Vasodilator Therapy , 1981, Circulation.

[47]  J. Cohn,et al.  Hyponatraemia as a marker for high renin heart failure. , 1982, British heart journal.

[48]  D. Ganten,et al.  Plasma angiotensin II concentrations and experimentally induced thirst. , 1981, The American journal of physiology.

[49]  M. Packer,et al.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.

[50]  J. Bonjour,et al.  Stimulation of ADH release by the renin-angiotensin system. , 1970, The American journal of physiology.

[51]  L. Horowitz,et al.  Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. , 1983, Journal of the American College of Cardiology.

[52]  E. Espiner,et al.  Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. , 1980, Clinical science.

[53]  D.,et al.  Regression Models and Life-Tables , 2022 .

[54]  B. Massie,et al.  Long‐term Vasodilator Therapy for Heart Failure: Clinical Response and its Relationship to Hemodynamic Measurements , 1981, Circulation.

[55]  M. Brown,et al.  Hypokalemia from beta 2-receptor stimulation by circulating epinephrine. , 1983, The American journal of cardiology.

[56]  J. Fitzsimons,et al.  The effect on drinking in the rat of intravenous infusion of angiotensin, given alone or in combination with other stimuli of thirst , 1969, The Journal of physiology.

[57]  N. Hollenberg,et al.  Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. , 1984, Annals of internal medicine.

[58]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.